达雷妥尤单抗治疗复发难治性多发性骨髓瘤的不良反应及护理对策  

Adverse Reactions and Nursing Strategies of Daratumumab in the Treatment of Relapsed and Refractory Multiple Myeloma

作　　者：王芳芳[1] 臧敏[1] WANG Fangfang;ZANG Min(The First People's Hospital of Nantong City,Nantong,Jiangsu 226000)

机构地区：[1]南通市第一人民医院,江苏南通226000

出　　处：《智慧健康》2025年第4期156-158,162,共4页Smart Healthcare

摘　　要：目的 通过分析达雷妥尤单抗治疗复发难治性多发性骨髓瘤产生的不良反应,探究针对性护理措施在减少药物副作用方面的效果。方法 将2022年1月—2022年12月本院收治的30例采用达雷妥尤单抗治疗复发难治性多发性骨髓瘤的患者纳入对照组,采用常规护理方法。将2023年1月—2023年12月本院收治的35例采用达雷妥尤单抗治疗复发难治性多发性骨髓瘤患者纳入观察组,对患者的不良反应情况进行专门的了解后,予以针对性护理干预。比较两组不良反应发生率、疼痛评分及症状自评评分。结果 观察组不良反应发生率比对照组低(P<0.05);护理前两组视觉模拟评分量表(visual analogue scale,VAS)评分比较,差异无统计学意义(P>0.05),护理后观察组VAS评分比对照组低(P<0.05);观察组症状自评量表阳性症状均分低于对照组(P<0.05)。结论 采用达雷妥尤单抗治疗复发难治性多发性骨髓瘤时,结合患者实际情况,制定针对性护理方案能降低不良反应发生率,减轻患者病痛反应,改善临床症状。Objective To analyze the adverse reactions of daratumumab in the treatment of relapsed and refractory multiple myeloma,and to explore the application effect of targeted nursing measures in reducing drug side effects.Methods A total of 30 patients with relapsed and refractory multiple myeloma treated with daratumumab in our hospital from January 2022 to December 2022 were selected as the control group,and conventional nursing methods were adopted.A total of 35 patients with relapsed and refractory multiple myeloma treated with daratumumab in our hospital from January 2023 to December 2023 were selected as the experimental group,and targeted nursing interventions were carried out after the adverse reactions of the patients were understood.The incidence of adverse reactions,pain scores and symptom self-rating scores were compared between the two groups.Results The adverse reaction rate of the experimental group was lower than that of the control group(P<0.05),there was no significant difference in VAS score between the two groups before nursing(P>0.05),and the VAS score of the experimental group was lower than that of the control group after nursing(P<0.05).The mean score of positive symptoms on the symptom self-rating scale in the observation group was lower than that in the control group,and the difference between the two groups was statistically significant(P<0.05)。Conclusion When using daratumumab to treat relapsed and refractory multiple myeloma,developing targeted nursing plans based on the patient's actual situation can reduce the incidence of adverse reactions,alleviate patient pain reactions,and improve clinical symptoms.

关 键 词：达雷妥尤单抗 复发难治性多发性骨髓瘤 不良反应 针对性护理 护理效果 

分 类 号：R473.73[医药卫生—护理学]